Senate Finance drug pricing bill is moving forward, with two critical amendments defeated by 14-14 tie votes. One would have stripped the inflation penalty from the bill, which probably would have killed any bipartisan momentum. The second targeted the Medicare Part B International Pricing Index and was defeated by a truly surprising set of votes.
For the biopharmaceutical industry there were two critical tie votes during the US Senate Finance Committee mark-up of the “Prescription Drug Pricing Reduction Act of 2019.”
Both came on amendments offered by Pennsylvania Republican Senator Pat Toomey: